New Recruiting Trial: Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
WHY IT MATTERS
This Phase 1 trial is now actively recruiting patients with Job syndrome complicated by lupus-like disease and/or atopic dermatitis — a rare combination that has limited treatment options and is being studied by the National Institute of Allergy and Infectious Diseases.
Researchers are testing a drug called baricitinib to see if it is safe and works well for patients with Job syndrome who also have lupus-like disease and/or atopic dermatitis (severe itchy skin). Job syndrome is a rare immune system disorder that makes it hard for the body to fight infections and causes skin problems. This is an early-stage study that will check for side effects and how well the drug works.
NCT ID: NCT07262983 Title: Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis Status: RECRUITING Phase: PHASE1 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Start date: 2026-04-05 URL: https://clinicaltrials.gov/study/NCT07262983 Source: UniteRare clinical trials database
ASK YOUR DOCTOR
If you have Job syndrome with lupus-like disease or atopic dermatitis, ask your immunologist or dermatologist whether you might be eligible for this trial and how to learn more at clinicaltrials.gov using NCT07262983.